Racial Differences in Disease Presentation and Management of Intracranial MeningiomaFunding This study involved no internal/external funding.
04 August 2018
13 November 2018
21 December 2018 (online)
Objective/Hypothesis The aim of the study was to determine the impact of race on disease presentation and treatment of intracranial meningioma in the United States.
Study Design This study comprised of the analysis of a national population-based tumor registry.
Methods Analysis of the surveillance, epidemiology, and end results (SEER) database was performed, including all patients identified with a diagnosis of intracranial meningioma. Associations between race, disease presentation, treatment strategy, and overall survival were analyzed in a univariate and multivariable model.
Results A total of 65,973 patients with intracranial meningiomas were identified. Of these, 45,251 (68.6%) claimed white, 7,796 (12%) black, 7,154 (11%) Hispanic, 4,902 (7%) Asian, and 870 (1%) patients reported “other-unspecified” or “other-unknown.” The median annual incidence of disease was lowest among black (3.43 per 100,000 persons) and highest among white (9.52 per 100,000 persons) populations (p < 0.001). Overall, Hispanic patients were diagnosed at the youngest age and white patients were diagnosed at the oldest age (mean of 59 vs. 66 years, respectively; p < 0.001). Compared with white populations, black, Hispanic, and Asian populations were more likely to present with larger tumors (p < 0.001). After controlling for tumor size, age, and treatment center in a multivariable model, Hispanic patients were more likely to undergo surgery than white, black, and Asian populations. Black populations had the poorest disease specific and overall survival rates at 5 years following surgery compared with other groups.
Conclusion Racial differences among patients with intracranial meningioma exist within the United States. Understanding these differences are of vital importance toward identifying potential differences in the biological basis of disease or alternatively inequalities in healthcare delivery or access Further studies are required to determine which factors drive differences in tumor size, age, annual disease incidence, and overall survival between races.
- 1 Agarwal V, McCutcheon BA, Hughes JD. , et al. Trends in management of intracranial meningiomas: analysis of 49,921 cases from modern cohort. World Neurosurg 2017; 106: 145-151
- 2 Curry Jr. WT, Barker II FG. Racial, ethnic and socioeconomic disparities in the treatment of brain tumors. J Neurooncol 2009; 93 (01) 25-39
- 3 Taylor AJ, Little MP, Winter DL. , et al. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol 2010; 28 (36) 5287-5293
- 4 Wang M, Chen C, Qu J. , et al. Inverse association between eczema and meningioma: a meta-analysis. Cancer Causes Control 2011; 22 (10) 1355-1363
- 5 Qi ZY, Shao C, Huang YL, Hui GZ, Zhou YX, Wang Z. Reproductive and exogenous hormone factors in relation to risk of meningioma in women: a meta-analysis. PLoS One 2013; 8 (12) e83261
- 6 Harris TJ, Cook DG, Wicks PD, Cappuccio FP. Ethnic differences in use of hormone replacement therapy: community based survey. BMJ 1999; 319 (7210): 610-611
- 7 Bethke L, Murray A, Webb E. , et al. Comprehensive analysis of DNA repair gene variants and risk of meningioma. J Natl Cancer Inst 2008; 100 (04) 270-276
- 8 Ding H, Liu W, Yu X, Wang L, Shao L, Yi W. Risk association of meningiomas with MTHFR C677T and GSTs polymorphisms: a meta-analysis. Int J Clin Exp Med 2014; 7 (11) 3904-3914
- 9 Ibebuike K, Ouma J. Demographic profile of patients diagnosed with intracranial meningiomas in two academic hospitals in Johannesburg, South Africa: a 12-month prospective study. Afr Health Sci 2014; 14 (04) 939-945
- 10 Kshettry VR, Ostrom QT, Kruchko C, Al-Mefty O, Barnett GH, Barnholtz-Sloan JS. Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. Neuro-oncol 2015; 17 (08) 1166-1173
- 11 Maile EJ, Barnes I, Finlayson AE, Sayeed S, Ali R. Nervous system and intracranial tumour incidence by Ethnicity in England, 2001-2007: a descriptive epidemiological study. PLoS One 2016; 11 (05) e0154347
- 12 Amezcua L, Rivas E, Joseph S, Zhang J, Liu L. Multiple sclerosis mortality by race/ethnicity, age, sex, and time period in the United States, 1999-2015. Neuroepidemiology 2018; 50 (1, 2): 35-40
- 13 Nicholson RA, Rooney M, Vo K, O'Laughlin E, Gordon M. Migraine care among different ethnicities: do disparities exist?. Headache 2006; 46 (05) 754-765
- 14 Inskip PD, Tarone RE, Hatch EE. , et al. Sociodemographic indicators and risk of brain tumours. Int J Epidemiol 2003; 32 (02) 225-233
- 15 Dolecek TA, Dressler EV, Thakkar JP, Liu M, Al-Qaisi A, Villano JL. Epidemiology of meningiomas post-public law 107-206: the benign brain tumor cancer registries amendment act. Cancer 2015; 121 (14) 2400-2410
- 16 Robertson JT, Gunter BC, Somes GW. Racial differences in the incidence of gliomas: a retrospective study from Memphis, Tennessee. Br J Neurosurg 2002; 16 (06) 562-566
- 17 Barnholtz-Sloan JS, Sloan AE, Schwartz AG. Racial differences in survival after diagnosis with primary malignant brain tumor. Cancer 2003; 98 (03) 603-609
- 18 Mukherjee D, Zaidi HA, Kosztowski T. , et al. Disparities in access to neuro-oncologic care in the United States. Arch Surg 2010; 145 (03) 247-253
- 19 Mukherjee D, Patil CG, Todnem N. , et al. Racial disparities in Medicaid patients after brain tumor surgery. J Clin Neurosci 2013; 20 (01) 57-61
- 20 Nuño M, Mukherjee D, Elramsisy A. , et al. Racial and gender disparities and the role of primary tumor type on inpatient outcomes following craniotomy for brain metastases. Ann Surg Oncol 2012; 19 (08) 2657-2663
- 21 Ward E, Jemal A, Cokkinides V. , et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 2004; 54 (02) 78-93
- 22 Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 2005; 294 (14) 1765-1772
- 23 Shin JY, Truong MT. Racial disparities in laryngeal cancer treatment and outcome: A population-based analysis of 24,069 patients. Laryngoscope 2015; 125 (07) 1667-1674
- 24 Molina MA, Cheung MC, Perez EA. , et al. African American and poor patients have a dramatically worse prognosis for head and neck cancer: an examination of 20,915 patients. Cancer 2008; 113 (10) 2797-2806
- 25 Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999; 341 (16) 1198-1205
- 26 Chan AK, McGovern RA, Brown LT. , et al. Disparities in access to deep brain stimulation surgery for Parkinson disease: interaction between African American race and Medicaid use. JAMA Neurol 2014; 71 (03) 291-299
- 27 Curry Jr. WT, Carter BS, Barker II FG. Racial, ethnic, and socioeconomic disparities in patient outcomes after craniotomy for tumor in adult patients in the United States, 1988-2004. Neurosurgery 2010; 66 (03) 427-437 , discussion 437–438
- 28 McClelland III S, Guo H, Okuyemi KS. Morbidity and mortality following acoustic neuroma excision in the United States: analysis of racial disparities during a decade in the radiosurgery era. Neuro-oncol 2011; 13 (11) 1252-1259